NCT06599216进行中（未招募）2 期
Adebrelimab Combined With Dalpicicliband Standard Endocrine Therapy for HR + / HER 2-breast Cancer:A Single-center,Open-label,Single-arm Clinical Trial
Harbin Medical University2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年10月8日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- tpCR rate
研究概览
简要总结
This study intends to explore the efficacy and safety of PD-L1 inhibitor Adebrelimab combined with the CDK4/6 inhibitor Dalpcicilib and standard endocrine therapy given as neoadjuvant treatment in stages II-III hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
详细描述
This single-center, open-label, single-arm clinical trial aims to evaluate the efficacy and safety of the neoadjuvant treatment with the PD-L1 inhibitor Adebrelimab in combination with the CDK4/6 inhibitor Dalpicicilib in combination with standard endocrine therapy, for stages II-III hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Postmenopausal women, aged ≥18 years;
- •Postmenopausal patients and all patients in the screening period must one of the following:
- •Previous bilateral oophorectomy, or aged ≥60 years;
- •Aged <60 years, natural Postmenopausal status (defined as spontaneous cessation for at least 12 consecutive months without other pathological or physiological causes), E2 and FSH at the postmenopausal level;
- •Histologically confirmed HR+/HER2- invasive breast cancer (specific definition: ER >10% tumor cell positive is defined as ER positive, PR >10% tumor cell positive is defined as PR positive, ER and/or PR positive is defined as HR positive; HER2 0-1+ or HER2 ++ but negative by FISH test, no amplification, defined as HER2 negative);
- •Histologically confirmed invasive breast cancer, stage II-III breast cancer diagnosed based on AJCC cancer staging system (8th edition) ;
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
- •According to the RECIST 1.1 standard, at least one measurable lesion exists;
- •The main organs have basically normal functions and meet the following conditions:
- •Bone marrow function: Hb≥90 g/L (no blood was transfused within 14 days); ANC≥1.5×109/L;PLT≥80×I09/L;
- •Liver and kidney function: TBlL≤1.5×ULN; ALT and AST≤3×ULN; serum Cr≤1.5 ULN and creatinine clearance>50 ml/min (Cockcroft-Gault formula);
- •Subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up.
排除标准
- •Previous use of CDK4/6 inhibitors or PD1/PD-L1 monoclonal antibody or concurrent treatment with any other antitumor therapy;
- •Severe organ dysfunction;
- •Inability to swallow,chronic diarrhea and intestinal obstruction,there are multiple factors that affect drug intake and absorption;
- •Patients with known HBV or HCV infection active phase or HBV DNA≥500, or chronic phase with abnormal liver function;
- •History of active autoimmune disease (such as interstitial pneumonia, colitis, hepatitis, pituitaritis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes)
- •History of immunodeficiency, including HIV testing positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation and allogeneic bone marrow transplantation; History of interstitial lung disease (except radiation pneumonia without hormone therapy) and non-infectious pneumonia;
- •History of any heart disease, including:1)medicated or clinically significant arrhythmia; 2) myocardial infarction; 3) heart failure; 4) any other cardiac disease judged by the investigator for the trial;
- •Patients during pregnancy and lactation, women of childbearing age who refuse to take effective contraceptive measures during the study period;
- •According to the discretion of the investigator, there are significant risks to patient safety or concomitant diseases affecting the patient's completion of the study (including but not limited to severe hypertension, severe diabetes, active infection);
- •Have a clear history of neurological or psychiatric disorders, including epilepsy or dementia;
- •Any condition deemed inappropriate for the patient's participation in this study by the investigator.
研究组 & 干预措施
Treatment Group
Experimental
干预措施: Adebrelimab+Dalpciclib+Standard Endocrine Therapy (Drug)
结局指标
主要结局
tpCR rate
时间窗: through study completion, an average of one and a half years
Total pathologic complete response (tpCR) rate, defined as ypT0/is, ypN0 as assessed by investigator.
次要结局
- OS(up to 3 years)
- EFS(up to 3 years)
- Ki67(Baseline and At Surgery)
- ORR(Baseline up to Cycle 5（each cycle is 28 days）)
研究者
Jinsong Wang
Professor of Treatment
Harbin Medical University
研究点 (2)
Loading locations...
相似试验
招募中
4 期
Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric AdenocarcinomaLocally Advanced Gastric AdenocarcinomaNCT06192186Yang Jianjun, PhD110
招募中
1 期
A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in CancerGastric CancerNCT06776770Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center52
招募中
2 期
Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract CarcinomaUnresectable Biliary Tract CarcinomaNCT06749730Henan Cancer Hospital63
撤回
不适用
Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)Esophageal Squamous Cell CarcinomaNCT06420908Hebei Medical University Fourth Hospital30
尚未招募
2 期
Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian CancerPlatinum-resistant Ovarian Cancer (PROC)ImmunotherapyNCT0660084137